Diagnosis
Rheumatoid arthritis
A chronic systemic autoimmune disease characterized by persistent symmetric bilateral polyarthritis (synovitis) that usually affects the hands and feet (may affect other joints) and extra-articular involvement (skin, heart, lungs, and eyes).
Etiology
Cause [ud4]
Unknown
Possible theory: Environmental trigger in a genetically predisposed host
Genetically susceptible individuals (carrier of HLA-DR4 or HLA-DR1) AND
External trigger (cigarette smoking, infection, or trauma)
Pathophysiology
Autoantibodies --> Inflammation
CD4 T cells, mononuclear phagocytes, fibroblasts, osteoclasts, neutrophils, B cells (RF), TNF-alpha, IL-1, IL-6, IL-8, TGF-ß, FGF, and PDGF
Arthritis --> synovial cell hyperplasia and cartilage/bone/tendon/ligament destruction
Chronic arthritis --> loss of cartilage and bone erosions
Distribution:
Joints: MCP, wrist, PIP, knee, MTP, shoulder, ankle, cervical spine, hip, elbow), synovial hypertrophy (pannus)
Extra-articular manifestations: Skin, heart, lungs, GI, vascular, hematologic, neurologic and eyes
Risk factors [rtx]
Genetics
Tobacco
Red meat intake
Vitamin D deficiency
Excessive coffee consumption
High salt intake
Complications [ud4]
Osteopenia and osteoporosis
Progressive deformity/disability
Venous thromboembolic disease
Anemia of chronic disease
Felty syndrome (splenomegaly and neutropenia)
Secondary Sjögren syndrome
Inflammatory eye disease
Rheumatoid vasculitis
Pulmonary manifestations: Pleuritis, bronchiolitis, and interstitial lung disease
Coronary artery disease
Lymphoma
Epidemiology
Incidence per 100.000 [onp][kqf][nm8][zme][qbc]
Symptoms & findings
Symptoms
Arthralgia, Arthritis, Fever, Keratoconjunctivitis sicca, Malaise, Muscle atrophy, Polyarthritis, Stiffness, Weakness
Clinical findings
ANA, Anemia, Ankylosis, Anti-CCP, Anti-MCV, Bone erosion, Carpal Tunnel Syndrome, Elevated CRP, Elevated Sedimentation Rate, Hydrops, Joint effusion, Leukocytosis, Osteoporosis, Pericardial effusion, Rheumatoid factor, Tenosynovitis, Thrombocytosis, Ulnar deviation
Anamneses
None listed.
Localized findings
Approach
Blood test: Erythrocyte sedimentation rate, CRP, complete blood count, Rheumatoid factor, Antinuclear antibody, Anti−cyclic citrullinated peptide antibody (anti-CCP) [rtx]
X-ray: Hands, wrists, knees, feet, elbows, shoulders, hips, cervical spine
MR: cervical columna
Ultrasound of joints
Arthrocentesis: microscopy, gram stain, cell count, culture, biopsy
Diagnostic criteria: 2010 ACR/EULAR Classification Criteria [rtx][ud4]
Joint involvement:
2-10 large joints = 1 point
1-3 small joints (MCP, PIP, wrist joints) = 2 points
4-10 small joints = 3 points
>10 joints = 5 points
Serology test results:
Low-positive RF or low-positive anti-CCP = 2 points
High-positive RF or high-positive anti-CCP = 3 points
Acute-phase reactant test results: Elevated CRP or ESR = 1 point
Duration of signs and symptoms: >6 weeks = 1 point
Score of ≥6 is classified as definite RA
Treatment
Conservative nonpharmacologic, nonsurgical therapies: [rtx]
Heat and cold therapies
Orthotics and splints
Therapeutic exercise
Occupational therapy
Adaptive equipment
Joint-protection education
Energy-conservation education
Nonbiologic disease-modifying antirheumatic drugs (DMARDs): [rtx]
Hydroxychloroquine
Azathioprine
Sulfasalazine
Methotrexate
Leflunomide
Cyclosporine
Gold salts
D-penicillamine
Minocycline
Biologic tumor necrosis factor (TNF)–inhibiting DMARDs: [rtx]
Etanercept
Infliximab
Adalimumab
Certolizumab
Golimumab
Biologic non-TNF DMARDs include the following: [rtx]
Rituximab
Anakinra
Abatacept
Tocilizumab
Sarilumab
Tofacitinib
Baricitinib
Upadacitinib
Other drugs used therapeutically include the following: [rtx]
Corticosteroids
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Analgesics
Surgical treatments include the following: [rtx]
Synovectomy
Tenosynovectomy
Tendon realignment
Reconstructive surgery or arthroplasty
Arthrodesis
Differential diagnoses
Carpal tunnel syndrome, Episcleritis, Fibromyalgia, Gout, Juvenile rheumatoid arthritis, Lyme disease, Osteoarthritis, Osteoporosis, Polymyalgia rheumatica, Psoriatic arthritis, Pyoderma gangrenosum, Reactive arthritis, Rheumatic fever, Sarcoidosis, Septic arthritis, Sjogren syndrome, Systemic lupus erythematosus, Uveitis
References
[1] Chauhan K, Jandu JS, Brent LH, et al. Rheumatoid Arthritis. [Updated 2023 May 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441999/
[2] http://emedicine.medscape.com/article/331715 (2014-01-27); [Medscape]
[3] Linos A, Worthington JW, O'Fallon WM, Kurland LT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol. 1980 Jan;111(1):87-98.
[4] Shi W, Liang X, Zhang H, Li H. Burden of rheumatoid arthritis in India from 1990 to 2021: insights from the Global Burden of Disease Database. Front Med (Lausanne). 2025 Feb 14;12:1526218.
[5] Lee H, Lee SI, Lim H, Kim HO, Kim RB, Cheon YH. Incidence Trends of Rheumatoid Arthritis in Korea for 11 Years (2006-2017). Clin Pract. 2024 Nov 13;14(6):2475-2483.
[6] Hanova P, Pavelka K, Dostal C, Holcatova I, Pikhart H. Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002-2003. Clin Exp Rheumatol. 2006 Sep-Oct;24(5):499-507.
[7] Lai CH, Lai MS, Lai KL, Chen HH, Chiu YM. Nationwide population-based epidemiologic study of rheumatoid arthritis in Taiwan. Clin Exp Rheumatol. 2012 May-Jun;30(3):358-63.